Welcome to the e-CCO Library!

P653: Ligation of the intersphincteric fistula tract vs. endorectal advancement flap for high perianal fistulas in Crohn’s disease: a retrospective cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. van Praag*1, M. Stellingwerf1, J. van der Bilt1, K. Gecse2, W. Bemelman1, C. Buskens1

Created: Friday, 22 February 2019, 9:41 AM
P653: Rheumatic extraintestinal manifestations in ulcerative colitis : Prevalence and predictive factors
Year: 2021
Source: ECCO'21 Virtual
Authors: mtir, M.(1);cherif, D.(1);kchir, H.(1);hassine, H.(1);maamouri, N.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P653: The changing epidemiology of IBD in the western world: a population-based study from Denmark
Year: 2022
Source: ECCO'22
Authors: Agrawal, M.(1);Christensen, H.(2);Bøgsted, M.(2);Colombel, J.F.(1);Jess, T.(2);Allin, K.(2);
Created: Friday, 11 February 2022, 3:56 PM
P653: The efficacy and safety of stem cell therapy for Crohn's disease: a meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Qiu Y.*1, Zhang S.-h.2, Mao R.1, Feng R.2, Zeng Z.-r.1, Chen M.-h.2

Created: Wednesday, 20 February 2019, 10:36 AM
P653: Tight control and Treat to target increase the rates of Transmural remission and Transmural response in Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Fernandes, S.R.(1,2)*;Bernardo, S.(1,2);Rita Gonçalves, A.(1,2);Moura dos Santos, P.(1,2);Valente, A.(1,2);Tato Marinho, R.(1,2);Correia, L.(1,2);
Created: Friday, 14 July 2023, 11:12 AM
P654 Influence of the interval of time between anti-TNF and vedolizumab or ustekinumab in the response to treatment in patients with inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

I. Bastón Rey1, M. Costa1, C. Calviño-Suarez1, V. Mauriz-Barreiro1, D. De la Iglesia1, J. Gonzalez2, R. Ferreiro-Iglesias1, J.E. Dominguez- Munoz1, M. Barreiro-de Acosta1

Created: Thursday, 30 January 2020, 10:12 AM
P654: Advances in optimalisation of therapeutic drug monitoring using mucosal TNF expression and anti-TNF concentration in patients with inflammatory bowel disease treated with biologicals: Preliminary results from a single-centre study
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Farkas1*, G. Elekes1, D. Kata2, I. Földesi2, S. Lada1, T. Ferenci3, T. Madácsy1, M. Rutka1, A. Bálint1, R. Bor1, A. Fábián1, A. Milassin1, Z. Szepes1, F. Nagy1, J. Maléth1, T. Molnár1

Created: Thursday, 21 February 2019, 9:14 AM
P654: Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry.
Year: 2022
Source: ECCO'22
Authors: González Muñoza, C.(1);Calafat, M.(2);Gisbert, J.P.(3);Iglesias, E.(4);Minguez, M.(5);Sicilia, B.(6);Esteve, M.(7);Gomollon, F.(8);Calvet, X.(9);Ricart, E.(10);Carpio, D.(11);Rivero, M.(12);Lopez-Sanroman, A.(13);Marquez, L.(14);Nos, P.(15);Cabriada, J.L.(16);Guardiola, J.(17);Garcia-Sepulcre, M.F.(18);Garcia-Lopez, S.(19);Lorente Poyatos, R.(20);Taxonera, C.(21);Barrio Andres, J.(22);Vera, I.(23);Domenech, E.(2);Garcia-Planella, E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P654: Controversies in the management of anti-TNF therapy in Crohn's disease patients. A Delphi consensus
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gonzalez Lama, Y.(1)*;Ricart, E.(2);Carpio, D.(3);Bastida, G.(4);Ceballos, D.(5);Ginard, D.(6);Marín-Jimenéz, I.(7);Menchén, L.(8);Muñoz, F.(9);
Created: Friday, 14 July 2023, 11:12 AM
P654: Monitoring of drug concentrations to predict remission under ustekinumab induction therapy in Crohn's disease patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Soufflet1, G. Boschetti1, X. Roblin3, C. Cuerq1,4, N. Williet3, R. Duclaux Loras5, P. Danion1, A. Mialon4, S. Paul6, B. Flourié1, S. Nancey*1

Created: Friday, 22 February 2019, 9:41 AM
P654: Mucosal healing with a second anti-TNF-α in patients with ulcerative colitis after the failure of the previous anti-TNF-α treatment
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Papa A., Pugliese D., D'Aversa F., De Vitis I., Landi R., Guidi L., Felice C., Gerardi V., Armuzzi A., Gasbarrini A., Rapaccini G.L.

Created: Wednesday, 20 February 2019, 10:36 AM
P654: Prevalence of Inflammatory Bowel Disease in young Greek Army male recruits from 2006 to 2018: a thirteen-year retrospective study from a tertiary center
Year: 2021
Source: ECCO'21 Virtual
Authors: Kyriakos, N.(1);Papaefthymiou, A.(2);Giakoumis, M.(1);Galanopoulos, M.(1);Galanis, P.(3);Mylonas, I.(1);Karatzas, P.(4);Mantzaris, G.(5);Liatsos, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P655 Pharmacokinetics of ustekinumab in children and adolescents with moderately to severely active Crohn’s disease: Results from UniStar, a phase 1 study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

O. Adedokun1, J. Hyams2, D. Turner3, A. Griffiths4, N. Terry5, L. Padgett5, D. Jacobstein6, C. O’Brien5, J. Rosh7

Created: Thursday, 30 January 2020, 10:12 AM
P655: A study to determine factors affecting clinical decision making in outpatients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Derwa Y.1, Gracie D.J.*1,2, Williams C.J.1, Sood R.1,2, Mumtaz S.1, Bholah M.H.1, Hamlin P.J.1, Ford A.C.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P655: Early life mebendazole exposure increases the risk of adult-onset ulcerative colitis: a population-based cohort study
Year: 2022
Source: ECCO'22
Authors: Agrawal, M.(1);Allin, K.(2);Iversen, A.(2);Mehandru, S.(1);Colombel, J.F.(1);Jess, T.(2);
Created: Friday, 11 February 2022, 3:56 PM
P655: Immunogenicity after transition from adalimumab to ABP 501 in patients with plaque psoriasis
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Mytych*, J. Miller, M. Starcevic Manning, I. Wala, H. Wang, N. Zhang, E. Krishnan, A. Kaliyaperumal

Created: Thursday, 21 February 2019, 9:14 AM
P655: Insulin Resistance Prevalence is Not Increased in Patients with Inflammatory Bowel Disease: a case-control study
Year: 2021
Source: ECCO'21 Virtual
Authors: Carrillo Palau, M.(1);Hernández-Camba, A.(2);Hernández Álvarez-Buylla, N.(1);Ramos, L.(1);Alonso-Abreu, I.(1);Vela, M.(2);Hernández-Pérez, A.(1);Arranz, L.(2);Hernández-Guerra, M.(1);Ferraz-Amaro, I.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P655: MadCAM1 Negativity of Lamina Propria Endothelial Cells is Associated with Non-Response to Vedolizumab in Inflammatory Bowel Disease Patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Zelinkova, Z.(1)*;Podmanicky, D.(2);Berakova, K.(3);Kadleckova, B.(1);
Created: Friday, 14 July 2023, 11:12 AM
P655: Microencapsulated Sodium Butyrate significantly modifies the microbiota in patients with inflammatory bowel disease mimicking prebiotic activity and proving effects on the treatment of the disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Facchin*1, N. Vitulo2, B. Perini1, A. Buda3, F. Zingone4, C. Romualdi5, R. D'Incà4, E. Savarino4

Created: Friday, 22 February 2019, 9:41 AM
P656 Clinical implications of endoscopic submucosal dissection in management of patients with ulcerative colitis-associated dysplasia
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Sakurai1, R. Nezu2, A. Okada3, Y. Komeda1, T. Nagai1, S. Masaki1, M. Yamada1, K. Takashima1, H. Kashida1, M. Kudo1

Created: Thursday, 30 January 2020, 10:12 AM